Clinical Efficacy of Patients With Secondary Bacteremia Treated With Omadacycline: Results From Phase 3 Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia Studies

Omadacycline for Community-Acquired Bacterial Pneumonia

(2019) Roman Stets et al.   NEW ENGLAND JOURNAL OF MEDICINE

Omadacycline for Acute Bacterial Skin and Skin-Structure Infections

(2019) William O’Riordan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antibiotic resistance profiles and multidrug resistance patterns of Streptococcus pneumoniae in pediatrics

(2019) Cai-yun Wang et al.   MEDICINE

Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial

(2019) William O'Riordan et al.   LANCET INFECTIOUS DISEASES

In VitroandIn VivoAntibacterial Activities of Omadacycline, a Novel Aminomethylcycline

(2013) A. B. Macone et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A systematic review of bacteremias in cellulitis and erysipelas

(2011) Craig G. Gunderson et al.   JOURNAL OF INFECTION

Safety and Efficacy of Intravenous Tigecycline in Subjects with Secondary Bacteremia: Pooled Results from 8 Phase III Clinical Trials

(2009) David Gardiner et al.   CLINICAL INFECTIOUS DISEASES

Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008

(2009) R Phillip Dellinger et al.   CRITICAL CARE MEDICINE